167 related articles for article (PubMed ID: 37831153)
21. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
23. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
[TBL] [Abstract][Full Text] [Related]
24. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
25. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
Anderson-Smits C; Baker ER; Hirji I
Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
27. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
[TBL] [Abstract][Full Text] [Related]
28. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.
Lin R; Wang Y; Huang F; Fan Z; Zhang S; Yang T; Xu Y; Xu N; Xuan L; Ye J; Sun J; Huang X; Liu Q
BMC Med; 2019 Aug; 17(1):156. PubMed ID: 31401973
[TBL] [Abstract][Full Text] [Related]
29. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
30. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
31. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
32. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of allogeneic hematopoietic stem cell transplantation in the treatment of 28 patients with hepatitis-related aplastic anemia].
Wang Y; Li J; Pang AM; Yang DL; Chen X; Zhang RL; Wei JL; Ma QL; Zhai WH; He Y; Jiang EL; Han MZ; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):628-634. PubMed ID: 37803835
[No Abstract] [Full Text] [Related]
34. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.
Jaskula E; Dlubek D; Sedzimirska M; Duda D; Tarnowska A; Lange A
Transplant Proc; 2010 Oct; 42(8):3273-6. PubMed ID: 20970670
[TBL] [Abstract][Full Text] [Related]
35. Characterization of IFNγ-producing natural killer cells induced by cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation.
Jin F; Lin H; Gao S; Wang H; Yan H; Guo J; Hu Z; Jin C; Wang Y; Wang Z; Zhao Y; Liu Y; Zheng X; Tan Y; Li W; Dai Y; Yang Y
Oncotarget; 2017 Jan; 8(1):51-63. PubMed ID: 27980216
[TBL] [Abstract][Full Text] [Related]
36. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma.
Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.
Luo YH; Yang J; Wei A; Zhu GH; Wang B; Zhang R; Jia CG; Yan Y; Wang K; Li S; Zhou X; Qin MQ; Wang TY
World J Pediatr; 2021 Dec; 17(6):626-636. PubMed ID: 34739695
[TBL] [Abstract][Full Text] [Related]
38. Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion.
Qi L; Huang X; He C; Ji D; Li F
J Int Med Res; 2021 Dec; 49(12):3000605211063292. PubMed ID: 34918995
[TBL] [Abstract][Full Text] [Related]
39. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
